DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award | HT942524KCRPPCFA

Opportunity Information: Apply for HT942524KCRPPCFA

The FY24 DoD Kidney Cancer Research Program (KCRP) Postdoctoral and Clinical Fellowship Award is a grant opportunity designed to support early-career scientists and physicians who have recently finished doctoral or medical training and are now pursuing postdoctoral and/or clinical fellowship work. The main goal is to help these trainees conduct innovative, high-impact kidney cancer research while also building the skills, publications, and mentorship foundation they need to launch an independent career as a kidney cancer research leader. The program is explicit that proposals should aim for meaningful advances in kidney cancer research and/or patient care, rather than small, incremental steps, and applicants are expected to clearly describe which kidney cancer patients or at-risk groups could ultimately benefit from the work.

A central theme of the award is "impact." The research is expected to have the potential to significantly accelerate progress toward better outcomes for kidney cancer, whether that impact is expected in the near term (for example, a new diagnostic approach) or longer term (for example, opening a new therapeutic strategy). The award supports a wide range of project maturity levels, including high-risk/high-reward ideas that are still early in development as well as projects backed by preliminary data that are positioned to move toward clinical translation. Regardless of stage, applications are expected to lay out a clear scientific rationale and a well-structured plan that reflects rigorous study design, including appropriate controls, statistical planning, and thoughtful discussion of pitfalls and alternative approaches.

The fellowship is structured so that the postdoctoral or clinical fellow is the Principal Investigator (PI), meaning the trainee is expected to take the lead in writing the key parts of the application, especially the project narrative and the researcher development plan, while receiving guidance from a mentor. Prior kidney cancer experience is not strictly required for the PI, but both the research project and the career development plan must be kidney cancer-focused. Reviewers will look closely at indicators that the PI is positioned to become independent, such as past achievements, honors, first-author publications, prior funding where applicable, and strong letters of recommendation that speak to research potential and commitment to the kidney cancer field.

Mentorship is treated as a core requirement rather than a formality. The mentor (and any co-mentor) must show they have the expertise needed to guide kidney cancer research and/or patient care, including recent publications and active funding, and they must demonstrate a real commitment to developing the fellow as a researcher. If the primary mentor does not have a strong kidney cancer track record, the program requires formal co-mentorship from an established kidney cancer investigator. The application must explain how the mentoring team will support both the science and the trainee's progression toward independence, and while an extensive prior mentoring record is helpful, a weaker mentoring history can be offset if the overall development plan and environment are particularly strong.

The researcher development plan is a major review focus. Applicants need to describe why the training environment is well-suited to their growth and lay out an individualized, kidney cancer-centered development roadmap, including the skills they will gain and how those skills will translate into independence. Multidisciplinary approaches are encouraged (though not mandatory), and applicants who integrate multiple disciplines should clearly explain how those pieces connect and strengthen the kidney cancer impact.

The funding announcement also highlights several broader Department of Defense and CDMRP emphasis areas that applicants may choose to align with when appropriate. These include nuclear medicine and related tools that could improve early diagnosis, precision imaging, or targeted therapies; women's health, including attention to sex as a biological variable and conditions affecting women differently; and alignment with recommendations from the congressionally mandated Metastatic Cancer Task Force aimed at accelerating translational and clinical research for advanced and recurrent cancers. In addition, the program stresses rigorous study design and transparent reporting practices to improve reproducibility and translation, reflecting widely accepted principles like randomization, blinding, sample-size estimation, and clear data handling.

Collaboration is strongly encouraged, especially partnerships involving military services, the Department of Veterans Affairs, academia, industry, and other federal entities. The intent is to leverage unique populations, datasets, infrastructure, or expertise that can make the research more impactful for Service Members, Veterans, and their families. If a project depends on special databases, samples, or other resources, the application must show that access is available at submission and include a plan to maintain that access throughout the project.

In terms of allowable research, studies involving human subjects, human data, and human specimens are permitted, but clinical trials are not allowed. The announcement draws a clear line between clinical trials (prospective assignment to an intervention to evaluate its effects on outcomes) and clinical research that is observational or otherwise does not test intervention safety or efficacy. Examples of permitted clinical research include studies of disease mechanisms, biomarker or imaging diagnostics, health disparities, technology development, epidemiology, outcomes research, and health services research, as long as they do not meet the regulatory definition of a clinical trial.

From a practical standpoint, awards will be made as grants. The anticipated maximum direct costs for the entire period of performance are capped at $195,000. The Army (USAMRAA) administers the opportunity under CFDA 12.420, with eligibility listed as unrestricted. The program expects to commit roughly $2.18 million total to fund about seven awards, with application funding dependent on federal fund availability, application volume, and the outcome of peer and programmatic review. The original application deadline is September 5, 2024, and awards supported with FY24 funds are expected to be made no later than September 30, 2025, with FY24 funds available for use through September 30, 2030.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-06-26.
• Applicants must submit their applications by 2024-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 7 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524KCRPPCFA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: